All In Biotech

Drug Trial Radar · NCT01959243

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Pediatric, Adult, and Geriatric Subjects

Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 507 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

507

Actual

Start

Feb 22, 2014

Primary completion

Apr 23, 2014

Study completion Jun 23, 2014

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
Collaborators
ORA, Inc.
First posted
Oct 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.

Conditions

  • Hyperemia

Interventions

  • Brimonidine TartrateDrug

    Ophthalmic solution to be applied as directed.

  • VehicleDrug

    Ophthalmic solution to be applied as directed.

  • Sodium FluoresceinDrug

    For use as needed during the study for evaluating corneal damage.

  • Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USPDrug

    For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 29

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 3

    Phoenix, Arizona

  • Bausch Site 4

    Havre de Grace, Maryland

  • Bausch Site 1

    Andover, Massachusetts

  • Bausch Site 2

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.